Ble nysgjerrig på effekten av dette så jeg søkte meg frem til noe... Den første studien her ble det brukt et produkt som heter 6-OXO, som er i praksis det samme som Novedex XT.
Effects of eight weeks of an alleged aromatase inhibiting nutritional supplement 6-OXO (androst-4-ene-3,6,17-trione) on serum hormone profiles and clinical safety markers in resistance-trained, eugonadal males
http://www.jissn.com/content/4/1/13Abstract:The purpose of this study was to determine the effects of 6-OXO, a purported nutritional aromatase inhibitor, in a dose dependent manner on body composition, serum hormone levels, and clinical safety markers in resistance trained males. Sixteen males were supplemented with either 300 mg or 600 mg of 6-OXO in a double-blind manner for eight weeks. Blood and urine samples were obtained at weeks 0, 1, 3, 8, and 11 (after a 3-week washout period). Blood samples were analyzed for total testosterone (TT), free testosterone (FT), dihydrotestosterone (DHT), estradiol, estriol, estrone, SHBG, leutinizing hormone (LH), follicle stimulating hormone (FSH), growth hormone (GH), cortisol, FT/estradiol (T/E). Blood and urine were also analyzed for clinical chemistry markers. Data were analyzed with two-way MANOVA. For all of the serum hormones, there were no significant differences between groups (p > 0.05). Compared to baseline, free testosterone underwent overall increases of 90% for 300 mg 6-OXO and 84% for 600 mg, respectively (p < 0.05). DHT underwent significant overall increases (p < 0.05) of 192% and 265% with 300 mg and 600 mg, respectively. T/E increased 53% and 67% for 300 mg and 600 mg 6-OXO, respectively. For estrone, 300 mg produced an overall increase of 22%, whereas 600 mg caused a 52% increase (p < 0.05). Body composition did not change with supplementation (p > 0.05) and clinical safety markers were not adversely affected with ingestion of either supplement dose (p > 0.05). While neither of the 6-OXO dosages appears to have any negative effects on clinical chemistry markers, supplementation at a daily dosage of 300 mg and 600 mg for eight weeks did not completely inhibit aromatase activity, yet significantly increased FT, DHT, and T/E.
Noen viktige detaljer:In regard to body composition, neither dose of 6-OXO demonstrated any significant improvement in fat mass or fat-free mass over the course of the study. Even with significant increases in FT and DHT, this furthers indicates that 6-OXO supplemented at these dosages for eight weeks did not decrease fat mass or cause an anabolic response by increasing muscle mass. Increased serum androgens levels have been shown to stimulate lipolysis due to increases in the activity of hormone sensitive lipase [21]; however, relative to the dosage and/or the duration of ingestion of 6-OXO on serum androgens in the present study, neither had any effect on body composition. In our previous study, eight weeks of supplementation with 72 mg/day of the nutritional aromatase inhibitor Novedex XT had no effect on fat-free mass, but was effective at producing a modest, but significant 3.5% decrease in fat mass when compared to placebo [16].
Konklusjon: The results of this study indicate that eight weeks of 6-OXO supplementation had no effect on body composition or clinical safety markers, but incompletely inhibited aromatase activity and significantly increased endogenous DHT levels that were attenuated after a three-week washout period. Therefore, while neither of the 6-OXO dosages appears to have any negative effects on clinical chemistry markers, supplementation at a daily dosage of 300 mg and 600 mg for eight weeks did not completely inhibit aromatase activity, yet significantly increased FT, DHT, and T/E.
Og denne:
Eight weeks of aromatase inhibition using the nutritional supplement Novedex XT: effects in young, eugonadal men.http://cyber-sport.us/zalaczniki/novedexarticle_153_114.pdfAbstract:This study examined the effects of an aromatase-inhibiting nutritional supplement on serum steroid hormones, body composition, and clinical safety markers. Sixteen eugonadal young men ingested either Novedex XT or a placebo daily for 8 wk, followed by a 3-wk washout period. Body composition was assessed and blood and urine samples obtained at weeks 0, 4, 8, and 11. Data were analyzed by 2-way repeated-measures ANOVA. Novedex XT resulted in average increases of 283%, 625%, 566%, and 438% for total testosterone (P=0.001), free testosterone (P=0.001), dihydrotestosterone (P=0.001), and the testosterone:estrogen ratio (P=0.001), respectively, whereas fat mass decreased 3.5% (P=0.026) during supplementation. No significant differences were observed in blood and urinary clinical safety markers or for any of the other serum hormones (P>0.05). This study indicates that Novedex XT significantly increases serum androgen levels and decreases fat mass.
